OXFORD, United Kingdom, Aug. 05, 2016 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM), the drug discovery
and development company advancing therapies for Duchenne muscular dystrophy and Clostridium difficile infection, announces
that Mr Erik Ostrowski, Chief Financial Officer, will present at the Canaccord Genuity Growth Conference, 11 August 2016 at 1:30pm
EDT in Boston.
A live audio webcast of the presentation will be available through the Investors section on the Company’s
website, www.summitplc.com. A replay of the webcast will be available soon after the live
presentation.
About Summit Therapeutics
Summit is a biopharmaceutical company focused on the discovery, development and commercialisation of novel medicines for
indications for which there are no existing or only inadequate therapies. Summit is conducting clinical programs focused on the
genetic disease, Duchenne muscular dystrophy, and the infectious disease, Clostridium difficile infection. Further
information is available at www.summitplc.com and Summit can be followed on Twitter (@summitplc).
For more information, please contact:
| |
|
Summit Therapeutics
Glyn Edwards / Richard Pye (UK office)
Erik Ostrowski / Michelle Avery (US office)
|
Tel: +44 (0)1235 443 951
+1 617 225 4455 |
Cairn Financial Advisers LLP
(Nominated Adviser)
Liam Murray / Tony Rawlinson
|
Tel: +44 (0)20 7148 7900 |
N+1 Singer
(Broker)
Aubrey Powell / Jen Boorer |
Tel: +44 (0)20 7496 3000 |
MacDougall Biomedical Communications
(US media contact)
Chris Erdman / Karen Sharma
|
Tel: +1 781 235 3060
cerdman@macbiocom.com
ksharma@macbiocom.com
|
Consilium Strategic Communications
(Financial public relations, UK)
Mary-Jane Elliott / Sue Stuart /
Jessica Hodgson / Lindsey Neville |
Tel: +44 (0)20 3709 5700
summit@consilium-comms.com
|
| |
|
-END-
